Showing 3111-3120 of 7016 results for "".
Molecular Profiling as a Cornerstone of Precision AML Therapy
https://reachmd.com/programs/cme/molecular-profiling-as-a-cornerstone-of-precision-aml-therapy/36178/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Exploring Timing in MS Therapy: Real-World Outcomes of Fumarates
https://reachmd.com/programs/neurofrontiers/exploring-timing-in-ms-therapy-real-world-outcomes-of-fumarates/32805/Redefining Risk in Endometrial Cancer: Recurrence Prediction with Machine Learning
https://reachmd.com/programs/project-oncology/redefining-risk-in-endometrial-cancer-recurrence-prediction-with-machine-learning/35508/A new study published in JCO Precision Oncology introduces a novel machine learning approach that could improve recurrence prediction in endometrial cancer. Though external validation remains a challenge, the results highlight a promising step towards personalized and proactive care for these pUnmasking IgG4-Related Disease: Best Practices for Accurate Diagnosis and Optimal Care
https://reachmd.com/programs/living-rheum/unmasking-igg4-related-disease-best-practices-for-accurate-diagnosis-and-optimal-care/32788/IgG4-related disease presents significant diagnostic challenges with diverse symptoms across organ systems. Dr. Matthew Baker, Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University and the Co-Founder and Co-Director of the Stanford Multidisciplinary SarcoidosTreating Primary Biliary Cholangitis with Seladelpar: Insights from the RESPONSE Trial
https://reachmd.com/programs/gi-insights/treating-primary-biliary-cholangitis-with-seladelpar-insights-from-the-response-trial/29162/Based on the RESPONSE trial, seladelpar may be a safe and effective treatment for primary biliary cholangitis patients who don’t response to current therapies.In The Pipeline: Phase 1, 2, and 3
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/pipeline-phase-1-2-and-3/29087/This summary provides the latest news on of some of the recent Phase 1, Phase 2, and Phase 3 clinical studies for psoriasis treatments.Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumabHow Air Pollution Affects the Skin
https://reachmd.com/programs/practical-dermatology/how-air-pollution-affects-the-skin/24041/An Interview with Dr. Mark Birch-MachinExploring Updates in the C. Difficile Treatment Landscape
https://reachmd.com/programs/gi-insights/exploring-updates-in-the-c-difficile-treatment-landscape/14628/From probiotics to proton pump inhibitors, learn more about the latest treatment considerations for C. difficile infection.Properly Diagnosing & Treating C. Difficile
https://reachmd.com/programs/gi-insights/properly-diagnosing-treating-c-difficile/14239/Is there concern among clinicians about potentially over-diagnosing patients with C. difficile? Find out.